169 related articles for article (PubMed ID: 38599716)
1. SGLT2 Inhibition: Neither a Diuretic nor a Natriuretic.
Packer M
J Am Coll Cardiol; 2024 Apr; 83(15):1399-1402. PubMed ID: 38599716
[No Abstract] [Full Text] [Related]
2. SGLT2 inhibitor and loop diuretic induce different vasopressin and fluid homeostatic responses in nondiabetic rats.
Masuda T; Ohara K; Vallon V; Nagata D
Am J Physiol Renal Physiol; 2022 Sep; 323(3):F361-F369. PubMed ID: 35900341
[TBL] [Abstract][Full Text] [Related]
3. Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function.
Vallon V; Verma S
Annu Rev Physiol; 2021 Feb; 83():503-528. PubMed ID: 33197224
[TBL] [Abstract][Full Text] [Related]
4. Early SGLT2 Inhibitors in Acute Heart Failure: Safe Diuretic-Sparing Strategy.
Costanzo MR; Januzzi JL
J Am Coll Cardiol; 2024 Apr; 83(14):1307-1309. PubMed ID: 38569759
[No Abstract] [Full Text] [Related]
5. SGLT2 inhibition in a kidney with reduced nephron number: modeling and analysis of solute transport and metabolism.
Layton AT; Vallon V
Am J Physiol Renal Physiol; 2018 May; 314(5):F969-F984. PubMed ID: 29361669
[TBL] [Abstract][Full Text] [Related]
6. Real-Life Prescribing of SGLT2 Inhibitors: How to Handle the Other Medications, Including Glucose-Lowering Drugs and Diuretics.
Lam D; Shaikh A
Kidney360; 2021 Apr; 2(4):742-746. PubMed ID: 35373039
[No Abstract] [Full Text] [Related]
7. SGLT2 Inhibition and Tubular Sodium Handling.
Palmer BF; Clegg DJ
J Am Soc Nephrol; 2024 Feb; 35(2):131-133. PubMed ID: 38129943
[No Abstract] [Full Text] [Related]
8. Critical Analysis of the Effects of SGLT2 Inhibitors on Renal Tubular Sodium, Water and Chloride Homeostasis and Their Role in Influencing Heart Failure Outcomes.
Packer M; Wilcox CS; Testani JM
Circulation; 2023 Jul; 148(4):354-372. PubMed ID: 37486998
[TBL] [Abstract][Full Text] [Related]
9. SGLT2 inhibition in chronic kidney disease: a preventive strategy against acute kidney injury at the same time?
Hasegawa S; Nangaku M
Kidney Int; 2022 Jan; 101(1):20-22. PubMed ID: 34991813
[TBL] [Abstract][Full Text] [Related]
10. Treatments for skeletal muscle abnormalities in heart failure: sodium-glucose transporter 2 and ketone bodies.
Takada S; Sabe H; Kinugawa S
Am J Physiol Heart Circ Physiol; 2022 Feb; 322(2):H117-H128. PubMed ID: 34860594
[TBL] [Abstract][Full Text] [Related]
11. Osmotic diuresis by SGLT2 inhibition stimulates vasopressin-induced water reabsorption to maintain body fluid volume.
Masuda T; Muto S; Fukuda K; Watanabe M; Ohara K; Koepsell H; Vallon V; Nagata D
Physiol Rep; 2020 Jan; 8(2):e14360. PubMed ID: 31994353
[TBL] [Abstract][Full Text] [Related]
12. Functional and Clinical Importance of SGLT2-inhibitors in Frailty: From the Kidney to the Heart.
Santulli G; Varzideh F; Forzano I; Wilson S; Salemme L; de Donato A; Lombardi A; Rainone A; Nunziata L; Jankauskas SS; Tesorio T; Guerra G; Kansakar U; Mone P
Hypertension; 2023 Sep; 80(9):1800-1809. PubMed ID: 37403685
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors.
Yakovleva T; Sokolov V; Chu L; Tang W; Greasley PJ; Peilot Sjögren H; Johansson S; Peskov K; Helmlinger G; Boulton DW; Penland RC
Diabetes Obes Metab; 2019 Dec; 21(12):2684-2693. PubMed ID: 31423699
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data.
Hallow KM; Greasley PJ; Helmlinger G; Chu L; Heerspink HJ; Boulton DW
Am J Physiol Renal Physiol; 2018 Nov; 315(5):F1295-F1306. PubMed ID: 30019930
[TBL] [Abstract][Full Text] [Related]
15. Similarities and distinctions between acetazolamide and sodium-glucose cotransporter 2 inhibitors in patients with acute heart failure: Key insights into ADVOR and EMPULSE.
Packer M; Butler J
Eur J Heart Fail; 2023 Sep; 25(9):1537-1543. PubMed ID: 37403655
[TBL] [Abstract][Full Text] [Related]
16. Antihyperglycemic agents as novel natriuretic therapies in diabetic kidney disease.
León Jiménez D; Cherney DZI; Bjornstad P; Castilla-Guerra L; Miramontes González JP
Am J Physiol Renal Physiol; 2018 Nov; 315(5):F1406-F1415. PubMed ID: 30066584
[TBL] [Abstract][Full Text] [Related]
17. Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science.
Cruz JE; Ahuja T; Bridgeman MB
Ann Pharmacother; 2018 Dec; 52(12):1238-1249. PubMed ID: 29911393
[TBL] [Abstract][Full Text] [Related]
18. Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease.
Bailey CJ; Day C; Bellary S
Curr Diab Rep; 2022 Jan; 22(1):39-52. PubMed ID: 35113333
[TBL] [Abstract][Full Text] [Related]
19. Nocturnal hypertension in diabetes: Potential target of sodium/glucose cotransporter 2 (SGLT2) inhibition.
Kario K; Weber M; Ferrannini E
J Clin Hypertens (Greenwich); 2018 Mar; 20(3):424-428. PubMed ID: 29457344
[No Abstract] [Full Text] [Related]
20. Renoprotective Effects of SGLT2 Inhibitors.
Vallon V
Heart Fail Clin; 2022 Oct; 18(4):539-549. PubMed ID: 36216484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
